Complications of reversible cerebral vasoconstriction syndrome in relation to age
- PMID: 37052670
- PMCID: PMC10267248
- DOI: 10.1007/s00415-023-11708-z
Complications of reversible cerebral vasoconstriction syndrome in relation to age
Abstract
Introduction: Reversible cerebral vasoconstriction syndrome (RCVS) has a heterogenous clinical and radiological presentation. We investigated whether RCVS complications vary according to age.
Patients and methods: In a pooled French cohort of 345 patients with RCVS, we assessed (1) rates of clinical and radiological complications, and (2) the functional outcome at 3 months according to age as a continuous variable, and in young patients aged ≤ 49 years versus those aged ≥ 50 years. The Commission Nationale Informatique et Liberté and the local ethics committee approved this study (registration number: 202100733).
Results: The risk for any focal deficit and for any brain lesion were independently associated with increasing age (OR 1.4, 95% CI 1.1-1.8; p = 0.014, and OR 1.6, 95% CI 1.2-2.1; p < 0.001, respectively). Subtypes of brain lesions independently associated with increasing age were subarachnoid haemorrhage (OR 1.7, 95% CI 1.3-2.3; p < 0.001) and intracerebral haemorrhage (OR 1.5, 95% CI 1.1-2.2; p = 0.023). Frequency of cervical artery dissections peaked at age 30-39, and young age was independently associated with cervical artery dissections (OR 13.6, 95% CI 2.4-76.6; p = 0.003). Age had no impact on the functional outcome, with a modified Rankin scale score of 0-1 in > 96% of patients.
Conclusion: Age seems to influence rates and types of complications of RCVS, with young age being associated with cervical artery dissections, and increasing age with haemorrhagic complications. If confirmed in larger prospective studies, recognition of age-specific patterns might help to guide clinical management and to identify complications in cases of RCVS and vice versa.
Keywords: Cerebrovascular diseases; Intracerebral haemorrhage; Reversible cerebral vasoconstriction syndrome; Stroke; Subarachnoid haemorrhage; Thunderclap headache.
© 2023. The Author(s).
Conflict of interest statement
KSL received travel and accommodation expenses from Acticor Biotech and Teva, not related to the submitted work. CR received honoraria for board membership and speaker fees Allergan/Abbvie, Homeperf, Lilly, Lundbeck, Mylan, Novartis, Ophtalmic, Orkyn, Pfizer, Sanofi and Teva, and travel, accommodation, and meeting expenses from Teva, Lundbeck and Lilly, all outside the submitted work. AD received honoraria for board membership and speaker fees from Allergan Abbvie, Lilly, Teva, Lundbeck, Pfizer and travel, accommodation, and meeting expenses from Teva, and SOS Oxygène, all outside the submitted work; she is associate editor of Cephalalgia. JM received travel, accommodation, and meeting expenses from SOS, GEP Sante, Lundbeck and Homeperf and received honoraria for advisory boards or speaker fees from Abbvie, Teva, Lilly, Lundbeck and Novartis not related to the submitted work; he is a member of the redaction committee of “La Lettre du Neurologue” without financial compensation. The other authors report no conflicts of interest.
Figures


References
MeSH terms
LinkOut - more resources
Full Text Sources